Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

ng and marketing expenses were $360,741 for the three month period ended June 30, 2007, an increase of 33% from $271,246 for the corresponding 2006 period.

General and administrative expenses of $1,248,605 for the second quarter of 2007 were up from $628,366 in the prior year period, primarily based on non-cash stock based compensation expense from options issued in April of 2007, and estimated accrued expenses associated with the delay in filing registration statements from previous preferred offerings

RECENT CORPORATE ACHIEVEMENTS:

Avicena announced plans for a confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) trial after meeting with the Food and Drug Administration (FDA). The confirmatory Phase III trial of the drug candidate, AL-02, for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), follows two completed studies demonstrating a positive trend towards increased survival.

Avicena announced patient enrollment on target in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial. The Phase III trial, sponsored by the NIH's National Institute of Neurological Disorders and Stroke (NINDS), is designed to evaluate the potential of Avicena's lead Parkinson's disease drug candidate, PD-02, in slowing disease progression. This trial will enroll over 1,720 patients and is one of the largest Parkinson's disease trials ever conducted.

Avicena announced advancement of Huntington's disease clinical program into Phase III in early 2008. Based on a dose-ranging study, Avicena selected an optimal dose of its novel drug candidate HD-02 for the treatment of Huntington's disease. The Company plans to initiate a Phase III trial in early 2008.

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust intellectual
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2
... genetics,(Nasdaq: DCGN ) today expressed its enthusiastic ... bill that, many years in the,making, is now ... be signed,promptly by President Bush. GINA would provide ... prohibiting discrimination against,individuals in matters of employment or ...
... April 25 Beckman,Coulter, Inc. (NYSE: BEC ... a quarterly dividend payout of seventeen cents ($0.17) ... 23, 2008 to all stockholders of,record on May ... payout of dividends., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ...
... BERLIN, April 25 Processes and products based ... the chemical industry in a wide range of ... the field of industrial,biotechnology in Germany will be ... Bioprocessing (April 27-30, 2008) in Chicago, Illinois.,The panel ...
Cached Biology Technology:deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 2deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 3deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 4World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2
(Date:7/10/2014)... stabilize or even improve the state of fisheries ... in the Mediterranean has deteriorated over the past ... fish species reported in the Cell Press journal ... call for stringent monitoring of Mediterranean fishing activities, ... plans in Mediterranean waters. , Their data show ...
(Date:7/10/2014)... Poor peepers are a problem, even if you are ... an imperious predator, scouring the shallow waters for any ... eye exam by Yale University scientists, you,re reduced to ... night. , Such is the lot of the giant ... new paper by Yale paleontologists, published in the journal ...
(Date:7/10/2014)... controversy centres around a family of enzymes known as ... group in their active site. At the centre of ... becomes oxidised (ferryl) when a reacting heme is in ... has remained unanswered for decades is whether this oxidation ... group (OH). Resolving this fundamental question has implications for ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Extinct sea scorpion gets a Yale eye exam, with surprising results 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3
... record of oxygen concentration in the earth's atmosphere shows that ... gave mammals the evolutionary boost they needed to dominate the ... and lead author of a paper published Sept. 30 ... have measured the abundance of carbon 13, a byproduct ...
... have learned how to selectively shut down a flyweight-sized ... that may help doctors better understand cancer, birth defects ... be reported this week in the online Proceedings of ... of genetic material called microRNAs. , Once thought to ...
... A team of researchers from the Department of Biochemistry ... the Universitat Autònoma de Barcelona has discovered that tetanus ... a therapy against psychological disorders such as depression, anxiety ... disorders such as Parkinson's disease. , Tetanus toxin is ...
Cached Biology News:Oxygen increase caused mammals to triumph, researchers say 2Micro-molecule plays big role in birth defects 2Tetanus toxin found to have therapeutic properties 2
...
...
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: